Bibliography for Copy of MD7512 Clinical Presentation & Management of Diabetes: Complications & Cardiovascular Disease

[1]
Abdul-Ghani, M. et al. 2017. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care. 40, 7 (Jul. 2017), 813–820. DOI:https://doi.org/10.2337/dc16-2736.

[2]
Adamsson Eryd, S. et al. 2017. Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up. Diabetic Medicine. 34, 3 (Mar. 2017), 411–418. DOI:https://doi.org/10.1111/dme.13266.

[3]
Andersson, D.P. et al. 2017. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. (Mar. 2017). DOI:https://doi.org/10.1136/heartjnl-2016-310746.

[4]
Atkinson, M.A. et al. 2014. Type 1 diabetes. The Lancet. 383, 9911 (Jan. 2014), 69–82. DOI:https://doi.org/10.1016/S0140-6736(13)60591-7.

[5]
Azmi, S. et al. 2017. Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study. Diabetologia. (Mar. 2017). DOI:https://doi.org/10.1007/s00125-017-4245-z.

[6]
Bangalore, S. et al. 2011. Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials. Circulation. 123, 24 (Jun. 2011), 2799–2810. DOI:https://doi.org/10.1161/CIRCULATIONAHA.110.016337.

[7]
Barzilay, J.I. et al. 2012. Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study. Circulation: Cardiovascular Quality and Outcomes. 5, 2 (Mar. 2012), 153–162. DOI:https://doi.org/10.1161/CIRCOUTCOMES.111.962522.

[8]
Bianchi, C. et al. 2013. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? Current Diabetes Reports. 13, 3 (Jun. 2013), 403–410. DOI:https://doi.org/10.1007/s11892-013-0371-2.

[9]
Bianchi, C. et al. 2013. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? Current Diabetes Reports. 13, 3 (Jun. 2013), 403–410. DOI:https://doi.org/10.1007/s11892-013-0371-2.

[10]
Black, J.A. et al. 2014. Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. British Journal of General Practice. 64, 621 (Apr. 2014), e208–e216. DOI:https://doi.org/10.3399/bjgp14X677833.

[11]
Boulton, A.J. et al. 2009. International collaborative research on Charcot’s disease - 2009. The Lancet. 373, 9658 (Jan. 2009), 105–106. DOI:https://doi.org/10.1016/S0140-6736(09)60019-2.

[12]
Boussageon, R. et al. 2011. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 343, jul26 1 (Jul. 2011), d4169–d4169. DOI:https://doi.org/10.1136/bmj.d4169.

[13]
Braffett, B.H. et al. 2016. Urogenital Autonomic Dysfunction in Diabetes. Current Diabetes Reports. 16, 12 (Dec. 2016). DOI:https://doi.org/10.1007/s11892-016-0824-5.

[14]
Çakici, N. et al. 2016. Systematic review of treatments for diabetic peripheral neuropathy. Diabetic Medicine. 33, 11 (Nov. 2016), 1466–1476. DOI:https://doi.org/10.1111/dme.13083.

[15]
Çakici, N. et al. 2016. Systematic review of treatments for diabetic peripheral neuropathy. Diabetic Medicine. 33, 11 (Nov. 2016), 1466–1476. DOI:https://doi.org/10.1111/dme.13083.

[16]
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes - ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673614607947.

[17]
Cefalu, W.T. et al. 2016. Getting to the "Heart” of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory”. Diabetes Care. 39, 5 (May 2016), 664–667. DOI:https://doi.org/10.2337/dc16-0405.

[18]
Chatterjee, S. et al. 2017. Type 2 diabetes. The Lancet. (Feb. 2017). DOI:https://doi.org/10.1016/S0140-6736(17)30058-2.

[19]
Cheung, N. et al. 2010. Diabetic retinopathy. The Lancet. 376, 9735 (Jul. 2010), 124–136. DOI:https://doi.org/10.1016/S0140-6736(09)62124-3.

[20]
Chloe L. Edridge 2015. Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. PLoS ONE. 10, 6 (2015). DOI:https://doi.org/doi: 10.1371/journal.pone.0126427.

[21]
Clokie, M. et al. 2017. New horizons in the understanding of the causes and management of diabetic foot disease: report from the 2017 Diabetes UK Annual Professional Conference Symposium. Diabetic Medicine. 34, 3 (Mar. 2017), 305–315. DOI:https://doi.org/10.1111/dme.13313.

[22]
Dahlöf, B. et al. 2005. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet. 366, 9489 (Sep. 2005), 895–906. DOI:https://doi.org/10.1016/S0140-6736(05)67185-1.

[23]
Dana Dabelea Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. JAMA. 317, 8, 825–835. DOI:https://doi.org/10.1001/jama.2017.0686.

[24]
Denig, P. et al. 2014. Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial. BMJ. 349, sep25 6 (Sep. 2014), g5651–g5651. DOI:https://doi.org/10.1136/bmj.g5651.

[25]
Dhatariya, K. et al. 2012. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. Diabetic Medicine. 29, 4 (Apr. 2012), 420–433. DOI:https://doi.org/10.1111/j.1464-5491.2012.03582.x.

[26]
Dhatariya, K.K. and Vellanki, P. 2017. Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA). Current Diabetes Reports. 17, 5 (May 2017). DOI:https://doi.org/10.1007/s11892-017-0857-4.

[27]
Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321.

[28]
Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321.

[29]
Duckworth, W. et al. 2009. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. New England Journal of Medicine. 360, 2 (Jan. 2009), 129–139. DOI:https://doi.org/10.1056/NEJMoa0808431.

[30]
Dwamena, F. et al. 1996. Interventions for providers to promote a patient-centred approach in clinical consultations. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[31]
Ele Ferrannini 2015. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. European Heart Journal. 36, 34 (2015), 2288–2296.

[32]
Elliott, W.J. and Meyer, P.M. 2007. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. The Lancet. 369, 9557 (Jan. 2007), 201–207. DOI:https://doi.org/10.1016/S0140-6736(07)60108-1.

[33]
Ferrannini, E. and Cushman, W.C. 2012. Diabetes and hypertension: the bad companions. The Lancet. 380, 9841 (Aug. 2012), 601–610. DOI:https://doi.org/10.1016/S0140-6736(12)60987-8.

[34]
Filippatos, T. et al. 2017. Pathophysiology of diabetic dyslipidaemia. Current Vascular Pharmacology. 15, 999 (Feb. 2017), 1–1.

[35]
Fisher, L. et al. 2014. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. Diabetic Medicine. 31, 7 (Jul. 2014), 764–772. DOI:https://doi.org/10.1111/dme.12428.

[36]
Foresta, C. et al. 2017. The great opportunity of the andrological patient: cardiovascular and metabolic risk assessment and prevention. Andrology. (Mar. 2017). DOI:https://doi.org/10.1111/andr.12342.

[37]
Fox, C.S. et al. 2015. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care. 38, 9 (Sep. 2015), 1777–1803. DOI:https://doi.org/10.2337/dci15-0012.

[38]
Gæde, P. et al. 2008. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. New England Journal of Medicine. 358, 6 (Feb. 2008), 580–591. DOI:https://doi.org/10.1056/NEJMoa0706245.

[39]
Gæde, P. et al. 2016. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 59, 11 (Nov. 2016), 2298–2307. DOI:https://doi.org/10.1007/s00125-016-4065-6.

[40]
Game, F. 2016. Classification of diabetic foot ulcers. Diabetes/Metabolism Research and Reviews. 32, (Jan. 2016), 186–194. DOI:https://doi.org/10.1002/dmrr.2746.

[41]
Giorgino, F. et al. 2016. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear? Diabetes Care. 39, Supplement 2 (Aug. 2016), S187–S195. DOI:https://doi.org/10.2337/dcS15-3023.

[42]
Giovanni Corona 2016. Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors. PLoS ONE. 11, 10 (2016). DOI:https://doi.org/doi: 10.1371/journal.pone.0157915.

[43]
Hayward, R.A. et al. 2015. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 372, 23 (Jun. 2015), 2197–2206. DOI:https://doi.org/10.1056/NEJMoa1414266.

[44]
Hayward, R.A. et al. 2015. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 372, 23 (Jun. 2015), 2197–2206. DOI:https://doi.org/10.1056/NEJMoa1414266.

[45]
Holman, R.R. et al. 2008. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine. 359, 15 (Oct. 2008), 1577–1589. DOI:https://doi.org/10.1056/NEJMoa0806470.

[46]
Holman, R.R. et al. 2017. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 377, 13 (Sep. 2017), 1228–1239. DOI:https://doi.org/10.1056/NEJMoa1612917.

[47]
Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[48]
Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[49]
Holt, R.I.G. et al. eds. 2017. Textbook of diabetes. Wiley Blackwell.

[50]
Holt, R.I.G. 2017. Understanding of the causes and management of diabetic foot disease. Diabetic Medicine. 34, 3 (Mar. 2017), 303–304. DOI:https://doi.org/10.1111/dme.13319.

[51]
Hotaling, J.M. et al. 2016. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. Diabetes Care. 39, 9 (Sep. 2016), 1587–1593. DOI:https://doi.org/10.2337/dc16-0059.

[52]
Hotaling, J.M. et al. 2016. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. Diabetes Care. 39, 9 (Sep. 2016), 1587–1593. DOI:https://doi.org/10.2337/dc16-0059.

[53]
Hypertension: Clinical Management of Primary Hypertension in Adults | NICE guideline 127. August 2011: http://www.nice.org.uk/guidance/cg127.

[54]
Ian Blumer, MD, FRCPC1, 2, Maureen Clement, MD, CCFP3, , Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges. Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges.

[55]
Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials- ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300998.

[56]
Jhamb, S. et al. 2016. Genetic and molecular basis of diabetic foot ulcers: Clinical review. Journal of Tissue Viability. 25, 4 (Nov. 2016), 229–236. DOI:https://doi.org/10.1016/j.jtv.2016.06.005.

[57]
Jin, D. et al. 2010. Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice. 89, 1 (Jul. 2010), 10–15. DOI:https://doi.org/10.1016/j.diabres.2010.03.021.

[58]
Johal, S. et al. 2017. Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study. Diabetic Medicine. (Jun. 2017). DOI:https://doi.org/10.1111/dme.13383.

[59]
Kaul, S. 2017. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care. 40, 7 (Jul. 2017), 821–831. DOI:https://doi.org/10.2337/dc17-0291.

[60]
Khunti, K. et al. 2013. Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people. Diabetes Care. 36, 11 (Nov. 2013), 3411–3417. DOI:https://doi.org/10.2337/dc13-0331.

[61]
Khunti, K. et al. 2015. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care. 38, 2 (Feb. 2015), 316–322. DOI:https://doi.org/10.2337/dc14-0920.

[62]
Khunti, K. et al. 2015. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care. 38, 2 (Feb. 2015), 316–322. DOI:https://doi.org/10.2337/dc14-0920.

[63]
Koye, D.N. et al. 2017. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. Diabetic Medicine. (Feb. 2017). DOI:https://doi.org/10.1111/dme.13324.

[64]
Kunutsor, S.K. et al. 2017. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabetic Medicine. 34, 3 (Mar. 2017), 316–327. DOI:https://doi.org/10.1111/dme.13133.

[65]
Liew, G. et al. 2009. Systemic management of diabetic retinopathy. BMJ. 338, feb12 1 (Feb. 2009), b441–b441. DOI:https://doi.org/10.1136/bmj.b441.

[66]
Lindholm, L.H. et al. 2002. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet. 359, 9311 (Mar. 2002), 1004–1010. DOI:https://doi.org/10.1016/S0140-6736(02)08090-X.

[67]
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data - ClinicalKey: https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716000036.

[68]
Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354.

[69]
Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354.

[70]
Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354.

[71]
Malavige, L.S. et al. 2015. The association between physical activity and sexual dysfunction in patients with diabetes mellitus of European and South Asian origin: The Oxford Sexual Dysfunction Study. European Journal of Medical Research. 20, 1 (Dec. 2015). DOI:https://doi.org/10.1186/s40001-015-0186-5.

[72]
Marso, S.P. et al. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 375, 4 (Jul. 2016), 311–322. DOI:https://doi.org/10.1056/NEJMoa1603827.

[73]
Matheus, A.S. de M. et al. 2013. Impact of Diabetes on Cardiovascular Disease: An Update. International Journal of Hypertension. 2013, (2013), 1–15. DOI:https://doi.org/10.1155/2013/653789.

[74]
Mayer-Davis, E.J. et al. 2017. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. New England Journal of Medicine. 376, 15 (Apr. 2017), 1419–1429. DOI:https://doi.org/10.1056/NEJMoa1610187.

[75]
Melanie Davies 2016. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clinical Pharmacology : Advances and Applications. 8, (2016). DOI:https://doi.org/doi: 10.2147/CPAA.S82008.

[76]
Micha, R. et al. 2017. Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. JAMA. 317, 9 (Mar. 2017). DOI:https://doi.org/10.1001/jama.2017.0947.

[77]
Miller, M.E. et al. 2010. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 340, jan08 1 (Jan. 2010), b5444–b5444. DOI:https://doi.org/10.1136/bmj.b5444.

[78]
Moreton, R.B.R. et al. 2017. Factors determining uptake of diabetic retinopathy screening in Oxfordshire. Diabetic Medicine. 34, 7 (Jul. 2017), 993–999. DOI:https://doi.org/10.1111/dme.13350.

[79]
Navaneethan, S.D. et al. 2017. Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD. American Journal of Kidney Diseases. (Feb. 2017). DOI:https://doi.org/10.1053/j.ajkd.2016.11.018.

[80]
Nicolucci, A. and Standl, E. 2011. Antiplatelet Therapy for Every Diabetic Person? Diabetes Care. 34, Supplement_2 (May 2011), S150–S154. DOI:https://doi.org/10.2337/dc11-s210.

[81]
Older antidiabetic drugs | The British Journal of Cardiology: https://bjcardio.co.uk/2018/03/older-antidiabetic-drugs/.

[82]
Omland, T. et al. 2016. Relation of Erectile Dysfunction to Subclinical Myocardial Injury. The American Journal of Cardiology. 118, 12 (Dec. 2016), 1821–1825. DOI:https://doi.org/10.1016/j.amjcard.2016.08.070.

[83]
Orchard, T.J. et al. 2015. Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. JAMA. 313, 1 (Jan. 2015). DOI:https://doi.org/10.1001/jama.2014.16107.

[84]
P Naidoo 2015. Lower limb complications of diabetes mellitus: a comprehensive review with clinicopathological insights from a dedicated high-risk diabetic foot multidisciplinary team. The British Journal of Radiology. 88, 1053 (2015). DOI:https://doi.org/doi: 10.1259/bjr.20150135.

[85]
Paul, S.K. et al. 2015. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology. 14, 1 (Dec. 2015). DOI:https://doi.org/10.1186/s12933-015-0260-x.

[86]
Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey: https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2213858718300020.

[87]
Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300020.

[88]
Personalised treatment targets in type 2 diabetes patients: The Dutch approach - ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1751991816300626.

[89]
Pickering, R.J. et al. 2018. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. Clinical & Translational Immunology. 7, 4 (2018). DOI:https://doi.org/10.1002/cti2.1016.

[90]
Piepoli, M.F. et al. 2016. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis. 252, (Sep. 2016), 207–274. DOI:https://doi.org/10.1016/j.atherosclerosis.2016.05.037.

[91]
Proceedings of the 5th International DAWN Summit 2014: Acting together to make person-centred diabetes care a reality - ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822715001862.

[92]
Rawshani, A. et al. 2017. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine. 376, 15 (Apr. 2017), 1407–1418. DOI:https://doi.org/10.1056/NEJMoa1608664.

[93]
Rawshani, A. et al. 2017. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine. 376, 15 (Apr. 2017), 1407–1418. DOI:https://doi.org/10.1056/NEJMoa1608664.

[94]
Ray, K.K. et al. 2009. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. The Lancet. 373, 9677 (May 2009), 1765–1772. DOI:https://doi.org/10.1016/S0140-6736(09)60697-8.

[95]
Richard W. Nesto 2008. LDL cholesterol lowering in type 2 diabetes: what is the optimum approach? Clinical Diabetes. 26, 1 (2008).

[96]
Ritholz, M.D. et al. 2017. Difficult conversations: adults with diabetes and the discussion of microvascular complications. Diabetic Medicine. (Jul. 2017). DOI:https://doi.org/10.1111/dme.13419.

[97]
Ritholz, M.D. et al. 2017. Difficult conversations: adults with diabetes and the discussion of microvascular complications. Diabetic Medicine. 34, 10 (Oct. 2017), 1447–1455. DOI:https://doi.org/10.1111/dme.13419.

[98]
Romero-Aroca, P. et al. 2017. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. British Journal of Ophthalmology. (Mar. 2017). DOI:https://doi.org/10.1136/bjophthalmol-2016-310063.

[99]
Romero-Aroca, P. et al. 2017. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. British Journal of Ophthalmology. (Mar. 2017). DOI:https://doi.org/10.1136/bjophthalmol-2016-310063.

[100]
Romero-Aroca, P. et al. 2017. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. British Journal of Ophthalmology. (Mar. 2017). DOI:https://doi.org/10.1136/bjophthalmol-2016-310063.

[101]
Rosenberg, J.B. and Tsui, I. 2017. Screening for Diabetic Retinopathy. New England Journal of Medicine. 376, 16 (Apr. 2017), 1587–1588. DOI:https://doi.org/10.1056/NEJMe1701820.

[102]
Saha, S.A. and Arora, R.R. 2010. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials. International Journal of Cardiology. 141, 2 (May 2010), 157–166. DOI:https://doi.org/10.1016/j.ijcard.2008.11.211.

[103]
Santi, D. et al. 2016. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. European Journal of Endocrinology. 174, 4 (Apr. 2016), 513–522. DOI:https://doi.org/10.1530/EJE-15-1100.

[104]
Schrier, R.W. et al. 1996. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. Diabetologia. 39, 12 (Nov. 1996), 1646–1654. DOI:https://doi.org/10.1007/s001250050629.

[105]
Scott, A.R. 2015. Management of hyperosmolar hyperglycaemic state in adults with diabetes. Diabetic Medicine. 32, 6 (Jun. 2015), 714–724. DOI:https://doi.org/10.1111/dme.12757.

[106]
Seidu, S. et al. 2016. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. Diabetic Medicine. 33, 3 (Mar. 2016), 280–289. DOI:https://doi.org/10.1111/dme.12885.

[107]
Soliman, E.Z. et al. 2017. Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 40, 6 (Jun. 2017), 793–799. DOI:https://doi.org/10.2337/dc16-2050.

[108]
Solomon, S.D. et al. 2017. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 40, 3 (Mar. 2017), 412–418. DOI:https://doi.org/10.2337/dc16-2641.

[109]
Solomon, S.D. et al. 2017. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418. Diabetes Care. 40, 6 (Jun. 2017), 809.3-809. DOI:https://doi.org/10.2337/dc17-er06e.

[110]
Solomon, S.D. et al. 2017. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418. Diabetes Care. (Apr. 2017). DOI:https://doi.org/10.2337/dc17-er06e.

[111]
Solomon, S.D. et al. 2017. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418. Diabetes Care. (Apr. 2017). DOI:https://doi.org/10.2337/dc17-er06e.

[112]
Sultan, A. et al. 2017. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. Diabetic Medicine. (Apr. 2017). DOI:https://doi.org/10.1111/dme.13364.

[113]
Sultan, A. et al. 2017. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. Diabetic Medicine. (Apr. 2017). DOI:https://doi.org/10.1111/dme.13364.

[114]
The changing face of diabetes complications - ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716300109.

[115]
The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management - ClinicalKey: https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0026049515003728.

[116]
The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management - NHS Health Check: http://www.healthcheck.nhs.uk/news/the_handbook_for_vascular_risk_assessment_risk_reduction_and_risk_management/.

[117]
Turnbull, F.M. et al. 2009. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 52, 11 (Nov. 2009), 2288–2298. DOI:https://doi.org/10.1007/s00125-009-1470-0.

[118]
Turnbull, F.M. et al. 2009. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 52, 11 (Nov. 2009), 2288–2298. DOI:https://doi.org/10.1007/s00125-009-1470-0.

[119]
UK Prospective Diabetes Study Group 1998. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ : British Medical Journal. 317, 7160 (1998).

[120]
Umpierrez, G. and Korytkowski, M. 2016. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nature Reviews Endocrinology. 12, 4 (Feb. 2016), 222–232. DOI:https://doi.org/10.1038/nrendo.2016.15.

[121]
Umpierrez, G. and Korytkowski, M. 2016. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nature Reviews Endocrinology. 12, 4 (Feb. 2016), 222–232. DOI:https://doi.org/10.1038/nrendo.2016.15.

[122]
Valencia, W.M. and Florez, H. 2017. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ. (Jan. 2017). DOI:https://doi.org/10.1136/bmj.i6505.

[123]
Wannamethee, S.G. et al. 2011. Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men: influence of age at onset, diabetes duration and established and novel rosk factors. Archives of Internal Medicine. 171, 5 (Mar. 2011). DOI:https://doi.org/10.1001/archinternmed.2011.2.

[124]
Webb, D.R. et al. 2016. Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. Diabetes/Metabolism Research and Reviews. (2016). DOI:https://doi.org/10.1002/dmrr.2877.

[125]
Weber, M.A. et al. 2010. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. Journal of the American College of Cardiology. 56, 1 (Jun. 2010), 77–85. DOI:https://doi.org/10.1016/j.jacc.2010.02.046.

[126]
Whelton, P.K. 2005. Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia. Archives of Internal Medicine. 165, 12 (Jun. 2005). DOI:https://doi.org/10.1001/archinte.165.12.1401.

[127]
White, J. et al. 2016. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. JAMA Cardiology. 1, 6 (Sep. 2016). DOI:https://doi.org/10.1001/jamacardio.2016.1884.

[128]
Wong, M.G. et al. 2016. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care. 39, 5 (May 2016), 694–700. DOI:https://doi.org/10.2337/dc15-2322.

[129]
Wong, M.G. et al. 2016. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care. 39, 5 (May 2016), 694–700. DOI:https://doi.org/10.2337/dc15-2322.

[130]
Yavuz, M. et al. 2017. Plantar Shear Stress in Individuals With a History of Diabetic Foot Ulcer: An Emerging Predictive Marker for Foot Ulceration. Diabetes Care. 40, 2 (Feb. 2017), e14–e15. DOI:https://doi.org/10.2337/dc16-2204.

[131]
Yudkin, J.S. et al. 2011. Intensified glucose control in type 2 diabetes—whose agenda? The Lancet. 377, 9773 (Apr. 2011), 1220–1222. DOI:https://doi.org/10.1016/S0140-6736(10)61112-9.

[132]
Zaccardi, F. et al. 2017. Predicting hospital stay, mortality and readmission in people admitted for hypoglycaemia: prognostic models derivation and validation. Diabetologia. (Mar. 2017). DOI:https://doi.org/10.1007/s00125-017-4235-1.

[133]
Zaccardi, F. et al. 2017. Risk factors and outcome differences in hypoglycaemia-related hospital admissions: A case-control study in England. Diabetes, Obesity and Metabolism. (Apr. 2017). DOI:https://doi.org/10.1111/dom.12941.

[134]
Zhang, C.-Y. et al. 2010. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis. Annals of Medicine. 42, 4 (May 2010), 305–315. DOI:https://doi.org/10.3109/07853891003796752.

[135]
Zinman, B. et al. 2015. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 373, 22 (Nov. 2015), 2117–2128. DOI:https://doi.org/10.1056/NEJMoa1504720.

[136]
Zoungas, S. et al. 2017. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. The Lancet Diabetes & Endocrinology. 5, 6 (Jun. 2017), 431–437. DOI:https://doi.org/10.1016/S2213-8587(17)30104-3.

[137]
Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality. Prime.

[138]
2010. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. The Lancet. 375, 9733 (Jun. 2010), 2215–2222. DOI:https://doi.org/10.1016/S0140-6736(10)60484-9.

[139]
2011. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. New England Journal of Medicine. 364, 9 (Mar. 2011), 829–841. DOI:https://doi.org/10.1056/NEJMoa1008862.

[140]
Diabetic foot problems: prevention and management | Guidance and guidelines | NICE.

[141]
1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 352, 9131 (Sep. 1998), 854–865. DOI:https://doi.org/10.1016/S0140-6736(98)07037-8.

[142]
2010. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine. 362, 17 (Apr. 2010), 1563–1574. DOI:https://doi.org/10.1056/NEJMoa1001282.

[143]
2005. Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus. Archives of Internal Medicine. 165, 12 (Jun. 2005). DOI:https://doi.org/10.1001/archinte.165.12.1410.

[144]
2010. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine. 362, 17 (Apr. 2010), 1575–1585. DOI:https://doi.org/10.1056/NEJMoa1001286.

[145]
2010. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine. 362, 17 (Apr. 2010), 1575–1585. DOI:https://doi.org/10.1056/NEJMoa1001286.

[146]
2008. Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine. 358, 24 (Jun. 2008), 2545–2559. DOI:https://doi.org/10.1056/NEJMoa0802743.

[147]
Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME - ClinicalKey.

[148]
2017. Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. New England Journal of Medicine. 376, 16 (Apr. 2017), 1507–1516. DOI:https://doi.org/10.1056/NEJMoa1612836.

[149]
Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes - ClinicalKey.

[150]
2008. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 358, 24 (Jun. 2008), 2560–2572. DOI:https://doi.org/10.1056/NEJMoa0802987.

[151]
2005. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. New England Journal of Medicine. 353, 25 (Dec. 2005), 2643–2653. DOI:https://doi.org/10.1056/NEJMoa052187.

[152]
2015. International Textbook of Diabetes Mellitus. John Wiley & Sons, Incorporated.

[153]
2011. Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. New England Journal of Medicine. 364, 9 (Mar. 2011), 818–828. DOI:https://doi.org/10.1056/NEJMoa1006524.

[154]
2017. Microvascular Complications and Foot Care. Diabetes Care. 40, Supplement 1 (Jan. 2017), S88–S98. DOI:https://doi.org/10.2337/dc17-S013.

[155]
2015. Minimizing Hypoglycemia in Diabetes: Table 1. Diabetes Care. 38, 8 (Aug. 2015), 1583–1591. DOI:https://doi.org/10.2337/dc15-0279.

[156]
2017. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine. 377, 3 (Jul. 2017), 300–301. DOI:https://doi.org/10.1056/NEJMc1706292.

[157]
1993. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine. 329, 14 (Sep. 1993), 977–986. DOI:https://doi.org/10.1056/NEJM199309303291401.

[158]
Type 1 diabetes in adults: diagnosis and management | Guidance and guidelines | NICE.

[159]
Type 2 diabetes in adults: management | Guidance and guidelines | NICE.

Bibliography for Copy of MD7512 Clinical Presentation & Management of Diabetes: Complications & Cardiovascular Disease BETA